Dr. Peter Turecek: iPATH Study and Key Biomarkers that Affect Bleeding Patterns for Hemophilia A

During the 60th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego in December 2018, Peter Turecek, Global Medical Affairs at Shire, discussed the Irish Personalized Approach to the Treatment of Hemophilia (iPATH) study, an ongoing collaboration investigating new personalized treatment approaches by tailoring care based on the needs of individual patients.

Patients in Ireland with hemophilia are registered at a single National Coagulation Centre where data on the use of factor concentrates and bleeding rates have already been collected. This provides a unique opportunity to conduct a hemophilia study aimed at better understanding the underlying biology of hemophilia with the goal of developing a personalized approach to hemophilia care that can then potentially be extended to the global hemophilia community. This clinical study approach also has the potential to be adapted for other diseases.